Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GelTex Pharmaceuticals (GELX) -- Ignore unavailable to you. Want to Upgrade?

To: Roader who wrote (50)	2/4/1998 1:51:00 PM
From: H. Bradley Toland, Jr.	Read Replies (1) \| Respond to of 127

Roader, I have not seen 1st Boston report but I do agree with the $50 price target for GELX.

To: Roader who wrote (50)	2/6/1998 12:32:00 PM
From: NY0001	Respond to of 127

Does anyone have access to the CSFB report or any other research on GELX? Could you post any of it, please? I find it interesting that CSFB is also covering GELX. They also cover RAISIO of Finland and just upgraded their targets on that company. Raisio has developed a cholesterol-lowering food addititve that J&J has licensed. These additives may eventually compete with the Cholesterol-lowering pharmaceutical market that GELX is in. Novartis recently signed a similar agreement with Forbes Medi-Tech (FMI.V) so it appears that this whole area of cholesterol-lowering foods may be accelerating and may impact the pharmaceutical side. Although, I note that FMI is also pursuing a cholesterol-lowering pharmaceutical as well as a food additive approach. Does the CSFB report address any of these issues?